Iqbal Muhammad Javed, Javed Zeeshan, Sadia Haleema, Mehmood Sajid, Akbar Ali, Zahid Benish, Nadeem Tariq, Roshan Sadia, Varoni Elena Maria, Iriti Marcello, Gürer Eda Sönmez, Sharifi-Rad Javad, Calina Daniela
Department of Biotechnology, University of Sialkot, Punjab, Pakistan.
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan.
Cancer Cell Int. 2023 May 6;23(1):84. doi: 10.1186/s12935-023-02929-3.
The clinical application of microRNAs in modern therapeutics holds great promise to uncover molecular limitations and conquer the unbeatable castle of cancer metastasis. miRNAs play a decisive role that regulating gene expression at the post-transcription level while controlling both the stability and translation capacity of mRNAs. Specifically, miR34a is a master regulator of the tumor suppressor gene, cancer progression, stemness, and drug resistance at the cell level in p53-dependent and independent signaling. With changing, trends in nanotechnology, in particular with the revolution in the field of nanomedicine, nano drug delivery systems have emerged as a prominent strategy in clinical practices coupled with miR34a delivery. Recently, it has been observed that forced miR34a expression in human cancer cell lines and model organisms limits cell proliferation and metastasis by targeting several signaling cascades, with various studies endorsing that miR34a deregulation in cancer cells modulates apoptosis and thus requires targeted nano-delivery systems for cancer treatment. In this sense, the present review aims to provide an overview of the clinical applications of miR34a regulation in targeted therapy of cancer.
微小RNA在现代治疗中的临床应用有望揭示分子层面的局限，并攻克癌症转移这座难以攻克的堡垒。微小RNA在转录后水平调控基因表达，同时控制信使核糖核酸的稳定性和翻译能力，发挥着决定性作用。具体而言，miR34a在p53依赖和非依赖信号通路中，是肿瘤抑制基因、癌症进展、干性和耐药性在细胞水平的主要调节因子。随着纳米技术的发展趋势变化，尤其是纳米医学领域的变革，纳米药物递送系统已成为临床实践中与miR34a递送相结合的突出策略。最近观察到，在人类癌细胞系和模式生物中强制表达miR34a，通过靶向多个信号级联反应来限制细胞增殖和转移，各种研究表明癌细胞中miR34a失调会调节细胞凋亡，因此癌症治疗需要靶向纳米递送系统。从这个意义上讲，本综述旨在概述miR34a调控在癌症靶向治疗中的临床应用。
